Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.
1. An immunoglobulin comprising:
a) a variable region of a heavy chain having an amino acid sequence that is at least 90% identical to SEQ ID NO: 7; and
b) a variable region of a light chain having an amino acid sequence that is at least 90% identical to SEQ ID NO: 14,
wherein the immunoglobulin comprises
a light chain variable region comprising a light chain complementary-determining region 1 (LCDR1) defined by SEQ ID NO: 41, LCDR2 defined by defined by SEQ ID NO: 32, and LCDR3 defined by SEQ ID NO: 22, and
a heavy chain variable region comprising a heavy chain complementary determining region 1 (HCDR1) defined by SEQ ID NO: 36, HCDR2 defined by defined by SEQ ID NO: 28, and HCDR3 defined by SEQ ID NO: 18.
2. The immunoglobulin according to claim 1 , wherein the immunoglobulin is a chimeric, humanized, or rat antibody.
3. A pharmaceutical composition comprising the immunoglobulin according to claim 1 , and one or more of a pharmaceutically acceptable excipient, a diluent and a carrier.
4. An immunoconjugate comprising the immunoglobulin according to claim 1 , linked to a therapeutic agent.